Models for early chemoprevention trials in breast cancer

C. J. Fabian, B. F. Kimler, R. M. Elledge, W. E. Grizzle, S. W. Beenken, J. H. Ward

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Several models are being explored for use in the phase I and phase II evaluation of breast cancer chemoprevention agents. The short-term DCIS/small invasive cancer model is probably best used in late phase I trials in conjunction with agents likely to have activity in earlier phases. The core biopsy of FNA hyperplasia models may be best used with drugs that are likely to have activity primarily in the promotion phase of neoplastic development and that are suitable for longer duration trials lasting several months to years. Morphology currently is the key surrogate endpoint biomarker for assessing efficacy in phase II trials. Other biomarkers that may undergo modulation will have to be validated, in that modulation will have to be shown to directly related to decreased cancer risk in subsequent phase III trials. Only then can they be considered as validated surrogate endpoint biomarkers and used as stand-alone efficacy markers in phase II trials. Despite accrual challenges and technologic hurdles, interest in phase I and phase II chemoprevention trials is high.

Original languageEnglish (US)
Pages (from-to)993-1017
Number of pages25
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Models for early chemoprevention trials in breast cancer'. Together they form a unique fingerprint.

Cite this